Irena Melnikova
Managing Director @ Burrill & Company
Irena Melnikova is a Series B investor at Burrill & Company focused on Biotechnology and Health Care. Irena Melnikova is the Managing Director at Burrill & Company. She attended UT Health San Antonio.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Irena Melnikova invests in
Stages Irena Melnikova invests in
Countries Irena Melnikova invests in
Investment Focus
Industry
- Biotechnology 4 (57%)
- Health Care 3 (43%)
- Medical 2 (29%)
- Life Science 2 (29%)
- Therapeutics 2 (29%)
Stage
- Series B 3 (43%)
- Seed 1 (14%)
- Series A 1 (14%)
Country
- United States 3 (43%)
- France 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
|
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M / Series B / Mar 18, 2026 | |
Enodia Therapeutics
|
Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | |
|
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $80M / Series A / Jul 11, 2023 | |
|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $123M / Series B / Mar 22, 2023 |
Co-Investors
Eli Lilly
4 deals together
Third Rock Ventures
4 deals together
Aditum Bio
2 deals together
Boxer Capital
2 deals together
Casdin Capital
2 deals together
Deep Track Capital
2 deals together
About Burrill & Company
Burrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
Burrill & Company Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Irena Melnikova
Managing Director
|
|||
Anna G. Annenko
Business Development Manager
|
|||
Ann F. Hanham
Managing Director
|
|||
Eduardo Marques de Souza Dantas Matto
Associate
|
|||
Holly Apgar
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Irena Melnikova invest in?
Irena Melnikova invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Irena Melnikova last invest?
The most recent investment recorded for Irena Melnikova closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
